Current strategies against multidrug-resistant Staphylococcus aureus and advances toward future therapy
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Antimicrobial resistance (AMR) has emerged as a formidable challenge in the treatment of infectious diseases, posing significant risks to global health. This issue is particularly with Staphylococcus aureus , a bacterium that can become multidrug-resistant (MDR), leading to severe complications and systemic infections due to their complex characteristics and diverse virulence factors. These new developments of AMR in S. aureus affected the scientific community in discovering the next generation of antibiotics, in which only two classes of antibiotics for clinical use have been introduced in the past two decades. This stagnation highlights the urgency of addressing AMR and the increasing difficulty in combating infections caused by superbug strains of staphylococcus. To overcome the AMR challenges, there is an urgent need to investigate and develop alternate therapy acts through a new target mechanism. In this review, we have discussed in brief several novel strategies such as bacteriophages, and antimicrobial peptides (AMP) to combat these MRSA infections. Emerging strategies such as CRISPR-Cas systems which allow for precise genetic editing, monoclonal antibodies designed to target specific bacterial toxins, bacterial phage therapies, and nanomedicine applications nanomedicine applications have been thoroughly discussed. Other than synthetic derivatives, the application of plant-based derivates, and repurposing drugs that exhibit anti-microbial properties, have been summarized. In an overview, this review provides advanced targets for investigators to develop new treatment strategies against MDR to improve the therapeutic efficacy and compliance of patients. • Multidrug-resistant Staphylococcus aureus (MRSA) is a major global health threat, increasing morbidity, mortality, and costs. • Treatment options are limited due to evolving resistance mechanisms. • New therapies like bacteriophages and antibiotic combinations are needed. • Technologies such as CRISPR, monoclonal antibodies, and nanomedicine show promise. • Plant-derived compounds, drug repurposing, and new antibiotics offer potential solutions
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“S. aureus remains a significant pathogen of global concern due to its remarkable adaptability, virulence, and ability to evade host immune defenses.”
From Staphylococcus aureus: A Review of the Pathogenesis and Virulence Mechanisms (2025) · cites this paper as [272]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Ch, S., Padaga, S. G., Ghosh, B., Roy, S., & Biswas, S. (2023) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2023.120822 · Cited by 40
Self-citationRetractedTacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D. L., Pulcini, C., Kahlmeter, G., Kluytmans, J., Carmeli, Y., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30753-3 · Cited by 6,142
David, M. Z., & Daum, R. S. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00081-09 · Cited by 1,972
A brief history of the antibiotic era: lessons learned and challenges for the future
Aminov, R. I. (2010) · Frontiers in Microbiology · doi:10.3389/fmicb.2010.00134 · Cited by 1,628
Ribosome-targeting antibiotics and mechanisms of bacterial resistance
Wilson, D. N. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3155 · Cited by 1,054
Howden, B. P., Davies, J. K., Johnson, P. D. R., Stinear, T. P., & Grayson, M. L. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00042-09 · Cited by 962
Horizontal Gene Transfer: From Evolutionary Flexibility to Disease Progression
Emamalipour, M., Seidi, K., Zununi Vahed, S., Jahanban-Esfahlan, A., Jaymand, M., Majdi, H., Amoozgar, Z., Chitkushev, L. T., Javaheri, T., Jahanban-Esfahlan, R., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00229 · Cited by 198
Research works printed but not linked: 122
- Abdallah, 2024, Staphylococcus aureus, Microb. Toxins Food Syst.: Causes Mech. Complicat., Metab., 235
- Abebe, 2023, Methicillin resistant Staphylococcus aureus: molecular mechanisms underlying drug resistance development and novel strategies to Combat, Infect. Drug Resist., 7641, 10.2147/IDR.S428103 · DOI · Paper page
- Adebisi, 2023, Balancing the risks and benefits of antibiotic use in a globalized world: the ethics of antimicrobial resistance, Glob. Health, 19, 27, 10.1186/s12992-023-00930-z · DOI
- Aide, M. (2023). "The Evolution of Sustainable Rice Production along the Lower Mississippi River (USA) with the Increasing Spector of Climate Change." · doi:10.5772/intechopen.112385
- Alaoui Mdarhri, 2022, Alternatives therapeutic approaches to conventional antibiotics: advantages, limitations and potential application in medicine, Antibiotics, 11, 1826, 10.3390/antibiotics11121826 · DOI · Paper page
- Aman, 2020, Nucleic acid detection using CRISPR/Cas biosensing technologies, ACS Synth. Biol., 9, 1226, 10.1021/acssynbio.9b00507 · DOI · Paper page
- Angelini, 2024, Plant-derived antimicrobials and their crucial role in combating antimicrobial resistance, Antibiotics, 13, 746, 10.3390/antibiotics13080746 · DOI · Paper page
- Anstead, G.M., J. Cadena and H. Javeri 2014. "Treatment of infections due to resistant Staphylococcus aureus." Methicillin-Resistant Staphylococcus aureus (MRSA) Protocols: 259-309. · DOI
- Anyaegbunam, 2022, The resurgence of phage-based therapy in the era of increasing antibiotic resistance: from research progress to challenges and prospects, Microbiol. Res., 264, 10.1016/j.micres.2022.127155 · DOI
- Baciu, 2024, The burden of antibiotic resistance of the main microorganisms causing infections in humans–review of the literature, J. Med. Life, 17, 246, 10.25122/jml-2023-0404 · DOI
- Bal, 2017, Future trends in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection: an in-depth review of newer antibiotics active against an enduring pathogen, J. Glob. Antimicrob. Resist., 10, 295, 10.1016/j.jgar.2017.05.019 · DOI
- Borges, 2015, Insights on antimicrobial resistance, biofilms and the use of phytochemicals as new antimicrobial agents, Curr. Med. Chem., 22, 2590, 10.2174/0929867322666150530210522 · DOI
- Bush, 2020, Epidemiology of β-lactamase-producing pathogens, Clin. Microbiol. Rev., 33, 10.1128/CMR.00047-19 · DOI · Paper page
- Ch, 2024, Cationized gelatin-sodium alginate polyelectrolyte nanoparticles encapsulating moxifloxacin as an eye drop to treat bacterial keratitis, Int. J. Biol. Macromol., 264, 10.1016/j.ijbiomac.2024.130457 · DOI
- Cheung, 2021, Pathogenicity and virulence of Staphylococcus aureus, Virulence, 12, 547, 10.1080/21505594.2021.1878688 · DOI · Paper page
- Chiu, 2016, Engineering antibody therapeutics, Curr. Opin. Struct. Biol., 38, 163, 10.1016/j.sbi.2016.07.012 · DOI · Paper page
- Coksu, 2024, Enhancing the treatment of Staphylococcus aureus infections: a nanosystem with including dual antimicrobial peptide, J. Drug Deliv. Sci. Technol., 97
- Cook, 2022, The past, present, and future of antibiotics, Sci. Transl. Med., 14, eabo7793, 10.1126/scitranslmed.abo7793 · DOI · Paper page
- Dale, 2018, Pharmacokinetics, tolerability, and safety of murepavadin, a novel antipseudomonal antibiotic, in subjects with mild, moderate, or severe renal function impairment, Antimicrob. Agents Chemother., 62, 10.1128/AAC.00490-18 · DOI
- Davies, 2003, Understanding biofilm resistance to antibacterial agents, Nat. Rev. Drug Discov., 2, 114, 10.1038/nrd1008 · DOI · Paper page
- Denardi, 2022, In vitro activity of the antimicrobial peptides h-Lf1-11, MSI-78, LL-37, fengycin 2B, and magainin-2 against clinically important bacteria, Braz. J. Microbiol., 1
- Duplessis, 2020, A review of topical phage therapy for chronically infected wounds and preparations for a randomized adaptive clinical trial evaluating topical phage therapy in chronically infected diabetic foot ulcers, Antibiotics, 9, 377, 10.3390/antibiotics9070377 · DOI
- Eckmann, 2010, Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin, Eur. J. Med. Res., 15, 554, 10.1186/2047-783X-15-12-554 · DOI
- Escalona, 2024, Polymicrobial methicillin-resistant Staphylococcus aureus bloodstream infections, Microbiol. Spectr.: e01081-01024, 10.1128/spectrum.01081-24 · doi:10.1128/spectrum.01081-24
- Falagas, 2013, MRSA in Africa: filling the global map of antimicrobial resistance, PloS One, 8, 10.1371/journal.pone.0068024 · DOI · Paper page
- Fapohunda, 2022, CRISPR Cas system: a strategic approach in detection of nucleic acids, Microbiol. Res., 259, 10.1016/j.micres.2022.127000 · DOI
- Farid, 2023, Repurposing Amphotericin B: anti-microbial, molecular docking and molecular dynamics simulation studies suggest inhibition potential of Amphotericin B against MRSA, BMC Chem., 17, 67, 10.1186/s13065-023-00980-9 · DOI
- Fauconnier, A.J. E. r 2017. "Regulating phage therapy: the biological master file concept could help to overcome regulatory challenge of personalized medicines." 18(2): 198-200. · DOI
- Fernández, L., D. Gutiérrez, P. García and A.J. A. Rodríguez (2019). "The perfect bacteriophage for therapeutic applications—a quick guide." 8(3): 126. · DOI
- Fodor, 2020, Multidrug resistance (MDR) and collateral sensitivity in bacteria, with special attention to genetic and evolutionary aspects and to the perspectives of antimicrobial peptides—a review, Pathogens, 9, 522, 10.3390/pathogens9070522 · DOI
- Gajdács, 2019, The continuing threat of methicillin-resistant Staphylococcus aureus, Antibiotics, 8, 52, 10.3390/antibiotics8020052 · DOI · Paper page
- Gebreyohannes, 2019, Challenges of intervention, treatment, and antibiotic resistance of biofilm-forming microorganisms, Heliyon, 5, 10.1016/j.heliyon.2019.e02192 · DOI · Paper page
- Georgopapadakou, 1980, Penicillin-binding proteins in bacteria, Antimicrob. Agents Chemother., 18, 148, 10.1128/AAC.18.1.148 · DOI · Paper page
- Girolomoni, 2016, Fusidic acid betamethasone lipid cream, Int. J. Clin. Pract., 70, 4, 10.1111/ijcp.12808 · DOI
- Goodridge, 2010, Des. phage Ther., 11, 15
- Gopikrishnan, 2024, Emerging strategies and therapeutic innovations for combating drug resistance in Staphylococcus aureus strains: a comprehensive review, J. Basic Microbiol., 64, 2300579, 10.1002/jobm.202300579 · DOI
- Grooters, 2024, Strategies for combating antibiotic resistance in bacterial biofilms, Front. Cell. Infect. Microbiol., 14, 1352273, 10.3389/fcimb.2024.1352273 · DOI · Paper page
- Grygiel, 2024, Comprehensive approaches to combatting acinetobacter baumannii biofilms: from biofilm structure to phage-based therapies, Antibiotics, 13, 1064, 10.3390/antibiotics13111064 · DOI
- Heine, 2024, Anti-biofilm properties of laser-synthesized, ultrapure silver–gold-alloy nanoparticles against Staphylococcus aureus, Sci. Rep., 14, 3405, 10.1038/s41598-024-53782-x · DOI
- Henostroza, 2022, Antibiotic-loaded lipid-based nanocarrier: a promising strategy to overcome bacterial infection, Int. J. Pharm., 621
- Hu, 2016, Molecular events for promotion of vancomycin resistance in vancomycin intermediate Staphylococcus aureus, Front. Microbiol., 7, 1601, 10.3389/fmicb.2016.01601 · DOI · Paper page
- Jayalakshmi, 2021, A review on antimicrobial resistance, diagnosis and an alternative approach, J. Entomol. Zool. Stud., 9, 1058
- Jin, 2024, Exploring the role of bacterial virulence factors and host elements in septic arthritis: insights from animal models for innovative therapies, Front. Microbiol., 15, 1356982, 10.3389/fmicb.2024.1356982 · DOI
- Kandaswamy, 2024, Synergistic berberine chloride and curcumin-loaded nanofiber therapies against methicillin-resistant staphylococcus aureus infection: augmented immune and inflammatory responses in zebrafish wound healing, Int. Immunopharmacol., 140, 10.1016/j.intimp.2024.112856 · DOI
- Kang, 2015, Glycopeptide antibiotics: structure and mechanisms of action, J. Bacteriol. Virol., 45, 67, 10.4167/jbv.2015.45.2.67 · DOI · Paper page
- Khan, 2018, Current and future treatment options for community-associated MRSA infection, Expert Opin. Pharmacother., 19, 457, 10.1080/14656566.2018.1442826 · DOI
- Konreddy, 2019, Recent drug-repurposing-driven advances in the discovery of novel antibiotics, Curr. Med. Chem., 26, 5363, 10.2174/0929867325666180706101404 · DOI · Paper page
- Kumar, 2024, Multidrug-resistant sepsis: a critical healthcare challenge, Antibiotics, 13, 46, 10.3390/antibiotics13010046 · DOI · Paper page
- Lagacé-Wiens, 2012, Adverse reactions to β-lactam antimicrobials, Expert Opin. Drug Saf., 11, 381, 10.1517/14740338.2012.643866 · DOI · Paper page
- Laudano, 2011, Ceftaroline fosamil: a new broad-spectrum cephalosporin, J. Antimicrob. Chemother., 66, iii11
- Lazzaro, 2020, Antimicrobial peptides: application informed by evolution, Science, 368, eaau5480, 10.1126/science.aau5480 · DOI · Paper page
- Li, 2024, Biocompatible formulation of a hydrophobic antimicrobial peptide L30 through nanotechnology principles and its potential role in mouse pneumonia model infected with Staphylococcus aureus, Colloids Surf. B: Biointerfaces, 236, 10.1016/j.colsurfb.2024.113823 · DOI
- Li, 2020, Recent advances in zinc oxide nanostructures with antimicrobial activities, Int. J. Mol. Sci., 21, 8836, 10.3390/ijms21228836 · DOI · Paper page
- Linz, 2023, Clinical impact of Staphylococcus aureus skin and soft tissue infections, Antibiotics, 12, 557, 10.3390/antibiotics12030557 · DOI · Paper page
- Liu, 2024, Staphylococcus aureus infections and human intestinal microbiota, Pathogens, 13, 276, 10.3390/pathogens13040276 · DOI · Paper page
- Liu, 2022, Circular guide RNA for improved stability and CRISPR-Cas9 editing efficiency in vitro and in bacteria, ACS Synth. Biol., 12, 350, 10.1021/acssynbio.2c00381 · DOI
- Liu, 2021, Drug repurposing for next-generation combination therapies against multidrug-resistant bacteria, Theranostics, 11, 4910, 10.7150/thno.56205 · DOI · Paper page
- Magana, 2020, The value of antimicrobial peptides in the age of resistance, Lancet Infect. Dis., 20, e216, 10.1016/S1473-3099(20)30327-3 · DOI · Paper page
- Maher, 2024, Bacterial skin and soft tissue infections in older adults, Clin. Geriatr. Med., 40, 117, 10.1016/j.cger.2023.09.006 · DOI
- Mahey, 2021, Repurposing approved drugs as fluoroquinolone potentiators to overcome efflux pump resistance in Staphylococcus aureus, Microbiol. Spectr., 9, 10.1128/Spectrum.00951-21 · DOI
- Makvandi, 2020, Metal-based nanomaterials in biomedical applications: antimicrobial activity and cytotoxicity aspects, Adv. Funct. Mater., 30, 1910021, 10.1002/adfm.201910021 · DOI · Paper page
- Mba, 2022, Focus: antimicrobial resistance: antimicrobial peptides therapy: an emerging alternative for treating drug-resistant bacteria, Yale J. Biol. Med., 95, 445
- Mba, 2022, Antimicrobial resistance: revisiting the mechanisms of resistance, Microbiol. Soc.
- McLaughlin, 1981, Unique features in the ribosome binding site sequence of the gram-positive Staphylococcus aureus beta-lactamase gene, J. Biol. Chem., 256, 11283, 10.1016/S0021-9258(19)68589-3 · DOI · Paper page
- Merabishvili, M., C. Vervaet, J.-P. Pirnay, D.De Vos, G. Verbeken, J. Mast, N. Chanishvili and M.J. P. o Vaneechoutte (2013). "Stability of Staphylococcus aureus phage ISP after freeze-drying (lyophilization)." 8(7): e68797. · DOI · Paper page
- Milton, 2009, The EMEA guideline on first-in-human clinical trials and its impact on pharmaceutical development, Toxicol. Pathol., 37, 363, 10.1177/0192623309332997 · DOI · Paper page
- Mishra, 2017, Host defense antimicrobial peptides as antibiotics: design and application strategies, Curr. Opin. Chem. Biol., 38, 87, 10.1016/j.cbpa.2017.03.014 · DOI · Paper page
- Moazed, 1987, Chloramphenicol, erythromycin, carbomycin and vernamycin B protect overlapping sites in the peptidyl transferase region of 23S ribosomal RNA, Biochimie, 69, 879, 10.1016/0300-9084(87)90215-X · DOI · Paper page
- Moellering Jr, 1998, Antibiotic resistance: lessons for the future, Clin. Infect. Dis., 27, S135, 10.1086/514902 · doi:10.1086/514902
- Mondal, 2024, Antimicrobial nanoparticles: current landscape and future challenges, RSC Pharm., 10.1039/D4PM00032C · DOI · Paper page
- Morales-Durán, 2024, Unraveling resistance mechanisms in combination therapy: a comprehensive review of recent advances and future directions, Heliyon, 10.1016/j.heliyon.2024.e27984 · DOI
- Muteeb, 2023, Origin of antibiotics and antibiotic resistance, and their impacts on drug development: a narrative review, Pharmaceuticals, 16, 1615, 10.3390/ph16111615 · DOI · Paper page
- Olatunji, 2024, Next-generation strategies to combat antimicrobial resistance: integrating genomics, CRISPR, and novel therapeutics for effective treatment, Eng. Sci. Technol. J., 5, 2284, 10.51594/estj.v5i7.1344 · DOI
- Oliveira, 2019, Repurposing ibuprofen to control Staphylococcus aureus biofilms, Eur. J. Med. Chem., 166, 197, 10.1016/j.ejmech.2019.01.046 · DOI
- Oyama, 2022, In silico identification of two peptides with antibacterial activity against multidrug-resistant Staphylococcus aureus, npj Biofilms Micro, 8, 58, 10.1038/s41522-022-00320-0 · DOI
- Pal, 2024, Methicillin-resistant staphylococcus aureus (Mrsa) remains a major threat to public health, Am. J. Public Health, 12, 48
- Pal, 2024, Phage therapy: an alternative treatment modality for MDR bacterial infections, Infect. Dis., 56, 785, 10.1080/23744235.2024.2379492 · DOI
- Pan, 1999, Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones, Antimicrob. Agents Chemother., 43, 1129, 10.1128/AAC.43.5.1129 · DOI
- Park, 2017, Genetic engineering of a temperate phage-based delivery system for CRISPR/Cas9 antimicrobials against Staphylococcus aureus, Sci. Rep., 7, 44929, 10.1038/srep44929 · DOI · Paper page
- Pătrașcu, 2024, Skin lesions with loss of tissue and cutaneous-onset sepsis: the skin infection–sepsis relationship, Diagnostics, 14, 659, 10.3390/diagnostics14060659 · DOI
- Peters, 2012, Polymicrobial interactions: impact on pathogenesis and human disease, Clin. Microbiol. Rev., 25, 193, 10.1128/CMR.00013-11 · DOI · Paper page
- Pinho, 2024, Liposomal rifabutin—a promising antibiotic repurposing strategy against methicillin-resistant staphylococcus aureus infections, Pharmaceuticals, 17, 470, 10.3390/ph17040470 · DOI
- Pinilla, 2021, Lipid-based nanostructures for the delivery of natural antimicrobials, Molecules, 26, 3587, 10.3390/molecules26123587 · DOI
- Presta, 2005, Selection, design, and engineering of therapeutic antibodies, J. Allergy Clin. Immunol., 116, 731, 10.1016/j.jaci.2005.08.003 · DOI
- Ramdan, 2024, Influences of improper use of antibiotics on public health, البحوث التطبيقية في العلوم والانسانيات, 1, 41, 10.21608/aash.2024.375733 · doi:10.21608/aash.2024.375733
- Rangel-Vega, 2015, Drug repurposing as an alternative for the treatment of recalcitrant bacterial infections, Front. Microbiol., 6, 282, 10.3389/fmicb.2015.00282 · DOI · Paper page
- Rawat, 2023, Nanobiomaterials: exploring mechanistic roles in combating microbial infections and cancer, Discov. Nano, 18, 158, 10.1186/s11671-023-03946-x · DOI
- Rončević, 2019, Antimicrobial peptides as anti-infective agents in pre-post-antibiotic era?, Int. J. Mol. Sci., 20, 5713, 10.3390/ijms20225713 · DOI
- Sabath, 1982, Mechanisms of resistance to beta-lactam antibiotics in strains of Staphylococcus aureus, Ann. Intern. Med., 97, 339, 10.7326/0003-4819-97-3-339 · DOI · Paper page
- Sangiorgio, 2024, The impact of enterococcus spp. in the immunocompromised host: a comprehensive review, Pathogens, 13, 409, 10.3390/pathogens13050409 · DOI
- Şen Karaman, 2021, Recent advances in the use of mesoporous silica nanoparticles for the diagnosis of bacterial infections, Int. J. Nanomed., 6575, 10.2147/IJN.S273062 · DOI
- Shahid, 2009, Beta-lactams and beta-lactamase-inhibitors in current-or potential-clinical practice: a comprehensive update, Crit. Rev. Microbiol., 35, 81, 10.1080/10408410902733979 · DOI
- She, 2024, Lusutrombopag as a repurposing drug in combination with aminoglycosides against vancomycin-resistant enterococcus, ACS Infect. Dis., 10, 1327, 10.1021/acsinfecdis.3c00737 · DOI
- She, 2022, Repurposing eltrombopag as an antimicrobial agent against methicillin-resistant Staphylococcus aureus, Front. Microbiol., 12, 10.3389/fmicb.2021.790686 · DOI
- Shen, 2024, Affinity molecular assay for detecting Candida albicans using chitin affinity and RPA-CRISPR/Cas12a, Nat. Commun., 15, 9304, 10.1038/s41467-024-53693-5 · DOI
- Sher, 2024, Current state and novel outlook on prevention and treatment of rising antibiotic resistance in urinary tract infections, Pharmacol. Ther., 10.1016/j.pharmthera.2024.108688 · DOI
- Shi, 2022, The antimicrobial peptide LI14 combats multidrug-resistant bacterial infections, Commun. Biol., 5, 926, 10.1038/s42003-022-03899-4 · DOI
- Singh, S., A. Numan, H.H. Somaily, B. Gorain, S. Ranjan, K. Rilla, H.R. Siddique, P.J. M.S. Kesharwani and E. C (2021). "Nano-enabled strategies to combat methicillin-resistant Staphylococcus aureus." 129: 112384. · DOI
- Speziale, 2021, Monoclonal antibodies targeting surface-exposed and secreted proteins from staphylococci, Vaccines, 9, 459, 10.3390/vaccines9050459 · DOI · Paper page
- Tabaja, 2021, Epidemiology of methicillin-resistant Staphylococcus aureus in arab countries of the middle east and north African (MENA) region, Mediterr. J. Hematol. Infect. Dis., 13, 10.4084/MJHID.2021.050 · DOI
- Tarai, 2013, Recurrent challenges for clinicians: emergence of methicillin-resistant Staphylococcus aureus, vancomycin resistance, and current treatment options, J. Lab. Physicians, 5, 071, 10.4103/0974-2727.119843 · DOI
- Tarín-Pelló, 2022, Antibiotic resistant bacteria: current situation and treatment options to accelerate the development of a new antimicrobial arsenal, Expert Rev. Anti-Infect. Ther., 20, 1095, 10.1080/14787210.2022.2078308 · DOI · Paper page
- Teng, 2023, Combatting resistance: understanding multi-drug resistant pathogens in intensive care units, Biomed. Pharmacother., 167, 10.1016/j.biopha.2023.115564 · DOI
- Theuretzbacher, 2020, The global preclinical antibacterial pipeline, Nat. Rev. Microbiol., 18, 275, 10.1038/s41579-019-0288-0 · DOI · Paper page
- Vacca, 2022, Monoclonal antibodies for bacterial pathogens: mechanisms of action and engineering approaches for enhanced effector functions, Biomedicines, 10, 2126, 10.3390/biomedicines10092126 · DOI
- Visca, 2019, The antimetabolite 3-bromopyruvate selectively inhibits Staphylococcus aureus, Int. J. Antimicrob. Agents, 53, 449, 10.1016/j.ijantimicag.2018.11.008 · DOI
- Wang, 2021, Antimicrobial peptides towards clinical application: delivery and formulation, Adv. Drug Deliv. Rev., 175, 10.1016/j.addr.2021.05.028 · DOI · Paper page
- Wang, 2020, Defeating antibiotic-resistant bacteria: exploring alternative therapies for a post-antibiotic era, Int. J. Mol. Sci., 21, 1061, 10.3390/ijms21031061 · DOI · Paper page
- Wang, 2022, Infection microenvironment-related antibacterial nanotherapeutic strategies, Biomaterials, 280, 10.1016/j.biomaterials.2021.121249 · DOI · Paper page
- Wang, 2020, CRISPR/cas systems redefine nucleic acid detection: principles and methods, Biosens. Bioelectron., 165, 10.1016/j.bios.2020.112430 · DOI · Paper page
- Wright, 1992, D-Alanyl-D-alanine ligases and the molecular mechanism of vancomycin resistance, Acc. Chem. Res., 25, 468, 10.1021/ar00022a006 · DOI · Paper page
- Wu, 2024, Hyaluronic acid-decorated curcumin-based coordination nanomedicine for enhancing the infected diabetic wound healing, Int. J. Biol. Macromol., 263, 10.1016/j.ijbiomac.2024.130249 · DOI
- Wurpts, 2019, Allergo J. Int., 28, 121, 10.1007/s40629-019-0100-8 · DOI
- Xiong, 2014, Delivery of antibiotics with polymeric particles, Adv. Drug Deliv. Rev., 78, 63, 10.1016/j.addr.2014.02.002 · DOI · Paper page
- Yamazaki, 2024, The role of Staphylococcus aureus quorum sensing in cutaneous and systemic infections, Inflamm. Regen., 44, 9, 10.1186/s41232-024-00323-8 · DOI
- Yedavally, 2023, Opportunities to apply nanomedicine in the treatment of Staphylococcus aureus infections, Invest. Staphylococcus aureus Intracell. Tactics Nanomed. Solut., 33
- Zhanel, 2012, Oritavancin: mechanism of action, Clin. Infect. Dis., 54, S214, 10.1093/cid/cir920 · DOI · Paper page
- Zhanel, 2009, Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.", Drugs, 69, 809, 10.2165/00003495-200969070-00003 · DOI
- Zhang, X., M.H. Marichannegowda, K.P. Rakesh and H.-L.J.M. r Qin 2018. "Master mechanisms of Staphylococcus aureus: consider its excellent protective mechanisms hindering vaccine development!" 212: 59-66. · DOI · Paper page
- Zhang, X., K. Rakesh, S.N.A. Bukhari, M. Balakrishna, H. Manukumar and H.-L.J.B.C. Qin 2018. "Multi-targetable chalcone analogs to treat deadly Alzheimer’s disease: Current view and upcoming advice." 80: 86-93. · DOI
- Zhang, X., H. Manukumar, K. Rakesh, C. Karthik, H.N. Prasad, S.N. Swamy, P. Mallu, Y.H. E. Mohammed and H.-L.J. M. p Qin (2018). "Role of BP* C@ AgNPs in Bap-dependent multicellular behavior of clinically important methicillin-resistant Staphylococcus aureus (MRSA) biofilm adherence: a key virulence study." 123: 275-284. · DOI · Paper page
- Zharkova, 2019, Application of antimicrobial peptides of the innate immune system in combination with conventional antibiotics—a novel way to combat antibiotic resistance?, Front. Cell. Infect. Microbiol., 9, 128, 10.3389/fcimb.2019.00128 · DOI · Paper page
Cited by
Staphylococcus aureus: A Review of the Pathogenesis and Virulence Mechanisms
Touaitia, R., Mairi, A., Ibrahim, N. A., Basher, N. S., Idres, T., & Touati, A. (2025) · Antibiotics · doi:10.3390/antibiotics14050470 · Cited by 273
Mafe, A. N., & Büsselberg, D. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17070820 · Cited by 18
Metadata
- Authors
- Kumar, S., Mahato, R. P., Ch, S., & Kumbham, S.
- ORCID
- Kumar, Saurabh
- Venue
- The Microbe
- Publisher
- Elsevier BV
- Published
- 2025-03
- Volume
- 6
- Pages
- 100281
- ISSN
- 2950-1946
- Cited by
- 68
- References
- 7
- Language
- en
- Update notices
- erratum (2025-09-01)
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.